Clinical Trials

Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

Trial Number—AT-101-CS-204

A randomized, double-blind phase II trial comparing the safety and efficacy of the combination of AT-101 and docetaxel with docetaxel alone in patients with relapsed/refractory non-small cell lung cancer.

Where is this study being conducted?

This study is being conducted at various sites within the United States, Russia, and the Ukraine.

Who is conducting the trial?

This trial is being sponsored by Ascenta Therapeutics, Inc.

Who can participate?

Adults with Stage IIIb non-small cell lung cancer or Stage IV non-small cell lung cancer, confirmed by a pathologist.

Patients must have progressed after 1 prior systemic chemotherapeutic regimen.

Patients with unstable or progressive brain metastases are not eligible.

What is AT-101?

AT-101 activates a pathway inside cancer cells resulting in the death of those cells. It is given by mouth in the form of pills.

What is docetaxel?

Docetaxel is a form of chemotherapy that nonspecifically kills cells that are rapidly dividing in the body, including cancer cells. It is given once every 3 weeks through an intravenous (IV) infusion over the course of 1 hour.

What do I do if I am interested in participating in this clinical trial?

Contact your physician. Your physician will be able to advise you about participating.

Trial Identification Number

NCT00544960